#hemepath on #AMLAwarenessDay
*Myeloid Sarcoma*
Extramedullary (out of BM) #AML
Resembles other poorly diff tumors
Eosinophilic myelocytes: clue (arrows)
Most sensitive IHC: CD43 (CD45:booby trap, more often - than +)
Monocytic diff common & CD34-
NPM1c IHC +~30% slam dunks Dx
Pleural effusion in a patient with history of DLBCL:
➡️Morphology good for AML
➡️Flow (+) only for CD56, CD71 & CD117 (all non-specific markers that can be expressed in an undifferentiated leukemia, but also in non-hematologic neoplasms) #hemepath#MedTwitter#surgpath#leusm
Sunday read: If you’re a hematopathologist (or aspiring one) you need to be able to distinguish Ph+ B-ALL from de novo presentation of B-lymphoid blast phase of CML: here’s the “why” and the “how”
#hemepath#leusm https://t.co/a2rZoGitRH
How I use p53 IHC to
screen for #TP53 mutation status in #AML#MDS
Recognize two abnormal patterns: overexpression (3+) & null (complete absence of staining in all neoplastic cells)
Only 3+ nuclei count for aberrant overexpression (don’t count 1+/ 2+) #hemepath#pathtwitter
@PVielh@CytopathologyJ My absolute pleasure! Such an honour to have been part of this venture and delighted to see the #CytoJ Twitter account flourishing in the hands of the most enthusiastic group of cytopathologists from around the 🌎
Now on to #monocytes… here is the normal immunophenotypic maturation patterns and a summary of common monocytic aberrancies in myeloid neoplasms #flowiccs#hemepath by Dr. Wei Wang of #hemepathMDA#leusm
Pathologists! What about this case of adult female with h/o B-ALL, treated, including allo-SCT, now with breast mass. Subsequent marrow was negative. Apparently an isolated extramedullary relapse of B-ALL. #hemepath#leukemia#lymphoma
The BLPG educational meeting continues this afternoon with Prof Leticia Quintanilla-Fend talking us through the ICC T-cell neoplasms, followed by an industry sponsored presentation on one centre’s experience of the use of lymphoma NGS panel.
Join in person or virtually @RCPath
1st day of the British Lymphoma Pathology Group educational meeting at RCPath @RCPath
Looking forward to great talks and discussion this morning lead by Dr Tom Butler (SIHMDS services) and Prof Elias Campo (ICC B-cell neoplasms).
Neck lymph node in an elderly person. Very difficult case which needed lots of IHC.
Follicles widely separated by collections of medium-sized cells. Some IHC in next tweet.
What other IHC would you like to see and what's the unifying diagnosis?
#hemepath
Lymphadenopathy in an Immunocompromised male patient. Not an effusion. CD20/PAX5 negative. EMA gorgeously positive. What do you think? #PathTwitter#hemepath
Burkitt lymphoma, EBV+, HIV setting
Per 5th edition of the WHO, a three-part nomenclature is now recommended:
1) Name of lesion
2) virus status
3) Type of immunodeficiency
Navigate the slides: https://t.co/hKLI92Q3YR | Case 3
#hemepath#lymsm#pathtwitter
Neck lymph node core biopsy from an adult.
CD20+, CD79a+, BCL2 weak, CD10+ in <30%, BCL6+, MUM1+, Ki67 high (>90%).
Just a boring non-GC DLBCL?
Strictly speaking, you can only call it DLBCL after excluding double/triple hit lymphoma.
#hemepath
Back with another episode of #WHOHEME this time covering what’s new (or old but gold) in Follicular Lymphoma #hemepath#LymSM … diagnostic pearls 🔬
@WHO 5th ed recognizes 5 flavors of FL… tune in & remember ISFBN, pediatric, duodenal and primary cutaneous are very indolent 1/
this is another article of the Virchows Archiv series "Updates on Eosinophilic Disorders" with the link to the full text: https://t.co/ZaFccDQkcg, @SocforHemepath#hemepath
Pathologists! What is your Dx for this cervical LN from male with cervical, supraclavicular & mediastinal LAD? Any more work up needed? #lymphoma#hemepath